Lim: ADC Drug Enhertu Has Reached Five Cancer Indications
Jonathan Lim · Biotech CEO on where we are in the fight to cure cancer · Apr 30, 2025 · at 7:19
Dr. Jonathan Lim, CEO of Erasca, highlights targeted therapies and antibody-drug conjugates in cancer treatment on the a16z Raising Health podcast.
0:00 / 0:14exact quote · 14.6s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Whether it's the, some of the ADCs, like Inheritu, where you see just remarkable long-term survival outcomes OS and PFS with in breast cancer, and now they're in five different indications, including tissue agnostic.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Jonathan Lim
Lim: 21-day water fast and plant diet cleared advanced lymphoma case
“Here's an example of a forty-two-year-old woman with advanced stage lymphoma. Her CT scan shows that before treatment, her lymph nodes were significantly enlarged. After a 21 day water only fast, you can see that her lymph nodes shrank pretty dramatically. She…”
Erasca claims its ERAS-15 molecular glue outperforms Revolution Medicines' RMC-6236
“And so we actually have our own cyclophiline A molecular glue called ERAS 15 that we just in-licensed, and we're really excited about that with Even higher potency than RMC six two three six”
Lim: Targeting ecDNA could become cancer treatment's fourth revolution
“Well, if we're successful, this would truly represent a fourth revolution in cancer treatment and could be used to compliment existing chemotherapeutic targeted therapy and cancer immunotherapy approaches to erase cancer.”
Biotech funding cycle has shifted away from platforms back to products
“I think the pendulum always swings back and forth between platforms and products and back again. I think we're back in the product cycle”